Androgen receptor signalling in non-prostatic malignancies: challenges and opportunities.

ABSTRACT: The androgen receptor (AR) signalling pathway has been intensively studied in the context of prostate cancer, where androgen deprivation therapy is part of the standard of care for metastatic disease. By contrast, fewer studies have investigated the impact and translational potential of targeting AR in other cancer types where it is also expressed and functional. In this Review, we discuss the current understanding of AR in non-prostatic cancer types and summarize ongoing AR-directed clinical trials. While different androgen levels contribute to sexual dimorphism in cancer, targeting the AR system could benefit both sexes and help overcome resistance to targeted therapies. However, a bimodal function of AR signalling, which suppresses stromal changes associated with the early stages of can

SUBMITTER: Dotto GP 

PROVIDER: S-EPMC11947662 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature